These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 29673776)

  • 21. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
    Niu C; Xie H; Aisa HA
    Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
    Huang MY; Armstrong AW
    Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
    Ryguła I; Pikiewicz W; Kaminiów K
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 25. Off-label Studies on the Use of Ruxolitinib in Dermatology.
    Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
    Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of janus kinase inhibitors in the treatment of alopecia areata.
    Triyangkulsri K; Suchonwanit P
    Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low rates of vaccination among atopic dermatitis, alopecia areata, psoriasis, and psoriatic arthritis patients on biologics.
    Hren MG; Khattri S
    Arch Dermatol Res; 2024 May; 316(6):285. PubMed ID: 38796548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
    Zhang L; Du D; Wang L; Guo L; Jiang X
    J Dermatol; 2021 Dec; 48(12):1877-1883. PubMed ID: 34487567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Under Development JAK Inhibitors for Dermatologic Diseases.
    Sideris N; Vakirlis E; Tsentemeidou A; Kourouklidou A; Ioannides D; Sotiriou E
    Mediterr J Rheumatol; 2020 Jun; 31(Suppl 1):137-144. PubMed ID: 32676572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of Baricitinib in Dermatology.
    Zhang J; Qi F; Dong J; Tan Y; Gao L; Liu F
    J Inflamm Res; 2022; 15():1935-1941. PubMed ID: 35330989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
    Ramot Y; Zlotogorski A
    Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
    Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
    PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Janus kinase inhibitors for alopecia areata: A narrative review.
    Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
    Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
    Fragoulis GE; McInnes IB; Siebert S
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Janus kinase inhibitors for skin disorders].
    Solimani F; Ghoreschi K
    Dermatologie (Heidelb); 2024 Oct; 75(10):781-790. PubMed ID: 39212722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
    Bayart CB; DeNiro KL; Brichta L; Craiglow BG; Sidbury R
    J Am Acad Dermatol; 2017 Jul; 77(1):167-170. PubMed ID: 28619556
    [No Abstract]   [Full Text] [Related]  

  • 37. JAK/STAT pathway modulation: Does it work in dermatology?
    Gündüz Ö
    Dermatol Ther; 2019 May; 32(3):e12903. PubMed ID: 30964573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
    Solimani F; Meier K; Ghoreschi K
    Front Immunol; 2019; 10():2847. PubMed ID: 31849996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Dermatology. New uses for JAK inhibitors in dermatology: a panacea, but at what price?].
    Russo G; Laffitte E; Cortes B
    Rev Med Suisse; 2024 Jan; 20(859):241-246. PubMed ID: 38299954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata.
    Blume-Peytavi U; Vogt A
    EBioMedicine; 2015 Apr; 2(4):282-3. PubMed ID: 26137570
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.